BioCentury
ARTICLE | Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

January 7, 2020 11:33 PM UTC
Updated on Jan 8, 2020 at 4:20 AM UTC

Rare metabolic disease company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) said Keith Gottesdiener will step down as CEO, president and a board member after more than eight years. He will stay on through the company’s submission of a rolling NDA to FDA this quarter for setmelanotide to treat pro-opiomelanocortin and leptin receptor deficiency obesities.

Mirati Therapeutics Inc. (NASDAQ:MRTX) hired Daniel Faga as EVP and COO and Benjamin Hickey as EVP and chief commercial officer. The company, which is one of the front-runners in the race to develop a K-Ras inhibitor, also promoted Vickie Reed to SVP of finance and chief accounting officer, and Jessica Corson to VP of business development. Faga was CBO at gene therapy company Spark Therapeutics Inc. (NASDAQ:ONCE) and Hickey was SVP and chief commercial officer at Halozyme Therapeutics Inc (NASDAQ:HALO)...